WFDC2 and ovarian carcinoma: Current strategies for epithelial ovarian cancer (EOC) screening use a combination of blood-based biomarkers, notably cancer antigen 125 (CA125; mucin 16 (MUC16)) and human epididymis protein (HE)-4, and trans-vaginal ultrasound imaging.